Nektar Secures $90M Jury Verdict Against Eli Lilly in Rezpeg License Dispute
NKTR sits 86% above its 52-week low of $33.4 on elevated volume (2.9× avg).
Summary
Nektar Therapeutics won a $90 million jury verdict against Eli Lilly in its breach-of-contract lawsuit over the rezpegaldesleukin license agreement. The award remains subject to post-trial proceedings and appeal.
Key Events · Legal and Risk Events · NKTR
-
Jury Verdict for Nektar
On September 24, 2026, a federal jury found Eli Lilly breached the implied covenant of good faith and fair dealing in the rezpegaldesleukin license agreement.
-
$90M Damages Award
The jury awarded Nektar $90 million in damages plus interest to be determined by the District Court.
-
Post-Trial Risk
The verdict remains subject to post-trial proceedings, and any resulting judgment may be appealed by Lilly.
-
Prior Market Reaction
Nektar shares fell 11% on September 22, 2026 as the jury deliberated; this verdict resolves the uncertainty in Nektar's favor.
Analysis · NKTR · Life Sciences
A federal jury found Eli Lilly breached the implied covenant of good faith and fair dealing in the license agreement governing the rezpegaldesleukin collaboration, awarding Nektar $90 million plus interest. The verdict is subject to post-trial proceedings and possible appeal, so the award is not yet final. Still, a favorable outcome in a high-stakes patent dispute with a major pharma partner removes a key overhang and could add meaningful cash to Nektar's balance sheet if upheld.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 35.9% of the 1030 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NKTR was trading at $62.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $33.40 to $109.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.